Latest Pyrazines Stories
Array MEK162 Phase 3 Trial Announced in Ovarian Cancer BOULDER, Colo., May 6, 2013 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today reported results for the third quarter of its fiscal year ending June 30, 2013. (Logo: http://photos.prnewswire.com/prnh/20121029/LA02195LOGO) Also today, Array announced the planned start of its first company-led Phase 3 trial with MEK162 in low-grade serous ovarian cancer. This is the third MEK162 pivotal trial that is expected to...
BEERSE, Belgium, April 26, 2013 /PRNewswire/ -- - OPTIMIZE study results presented at EASL show similar sustained virological response (SVR12) rates in patients with fibrosis or cirrhosis receiving an INCIVO(R)(telaprevir) combination treatment twice daily versus every eight hours - Janssen Infectious Diseases-Diagnostics BVBA (Janssen), announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency...
BOULDER, Colo., April 4, 2013 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced that results from two ongoing ARRY-520 clinical trials in multiple myeloma (MM) were presented at the 2013 International Myeloma Workshop in Kyoto, Japan. ARRY-520 is a potent, selective KSP inhibitor with a mechanism of action distinct from other drugs used to treat MM that continues to advance in clinical trials. (Logo: http://photos.prnewswire.com/prnh/20121029/LA02195LOGO) Results...
BOSTON, Massachusetts, November 10, 2012 /PRNewswire/ -- - Study presented at American Association for the Study of Liver Diseases 2012 shows high sustained virological response (SVR) in HCV/HIV co-infected patients receiving INCIVO(R) (telaprevir)-based regimen - Janssen Infectious Diseases-Diagnostics BVBA (Janssen) today presented results from a new phase 2 study which shows that an INCIVO(R) (telaprevir)-based regimen was effective in...
STOCKHOLM, November 1, 2012 /PRNewswire/ -- - Companies to evaluate a two-drug combination of Medivir/Janssen's investigational protease inhibitor simeprevir (TMC435) and Vertex's investigational nucleotide analogue VX-135 - Phase II proof-of-concept study to begin in early 2013 to evaluate safety, tolerability and viral cure rates of 12-week treatment regimen Medivir AB (OMX: MVIR), announced today plans for a phase...
NEW YORK, Oct. 17, 2012 /PRNewswire/ -- As part of its ongoing mission to recognize the technical, scientific and clinical research skills necessary to develop innovative medicines, the Prix Galien USA committee last night honored excellence in scientific innovation that improves the state of human health at its sixth annual Prix Galien Awards Gala, held at the American Museum of Natural History in New York City. Led by honorary member and Nobel Peace Prize winner Professor Elie...
BEERSE, Belgium, October 16, 2012 /PRNewswire/ -- NOT INTENDED FOR US JOURNALISTS - OPTIMIZE study results to be presented in late-breaking poster presentation at the American Association for the Study of Liver Diseases (AASLD) 2012 show non-inferior sustained virological response (SVR12) rates in previously untreated genotype-1 patients receiving an INCIVO(R) (telaprevir) based regimen twice-daily versus...
SUNNYVALE, Calif., Aug. 20, 2012 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) announced today that the clinical trial, SPARK (MCL2001), of ibrutinib in patients with relapsed or refractory mantle cell lymphoma (MCL) has enrolled its fifth patient. The enrollment of the fifth patient has subsequently triggered a second $50 million milestone payment obligation from Janssen Biotech, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, worldwide...
SOUTH SAN FRANCISCO, Calif., July 2, 2012 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced today that the company has begun enrollment in the ENDEAVOR trial, a Phase 3 trial evaluating Kyprolis(TM) (proposed brand name for carfilzomib) in combination with dexamethasone, versus bortezomib (Velcade®) with dexamethasone in patients with relapsed multiple myeloma. "The ENDEAVOR trial is the first head-to-head trial conducted with Kyprolis, and is an important step in...
QUEBEC CITY, June 28, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that its Japanese partner Yakult Honsha ("Yakult") (Tokyo: 2267) has initiated a Phase 1 trial in multiple myeloma, a form of blood cancer, with perifosine, the Company's oral Akt/PI3K inhibitor drug. Yakult, who are sponsoring and conducting this trial in Japan, reported that a first patient has been treated with perifosine. This is an open-label, two...
